|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance显示文摘 | James A. McCubrey Linda S. Steelman William H. Chappell Stephen L. Abrams Ellis W.T. Wong Fumin Chang Brian Lehmann David M. Terrian Michele Milella Agostino Tafuri Franca Stivala Massimo Libra Jorg Basecke Camilla Evangelisti Alberto M. Martelli Richard | 2006 | BBA - Molecular Cell Research2006，，8： | 3 |
| 2 | Metastatic pancreatic cancer: Is there a light at the end of the tunnel?显示文摘Due to extremely poor prognosis,pancreatic cancer(PDAC)represents the fourth leading cause of cancerrelated death in Western countries.For more than a decade,gemcitabine(Gem)has been the mainstay of first-line PDAC treatment.Many efforts aimed at improving single-agent Gem efficacy by either combining it with a second cytotoxic/molecularly targeted agent or pharmacokinetic modulation provided disappointing results.Recently,the field of systemic therapy of advanced PDAC is finally moving forward.Polychemotherapy has shown promise over single-agent Gem:regimens like PEFG-PEXG-PDXG and GTX provide significant potential advantages in terms of survival and/or disease control,although sometimes at the cost of poor tolerability.The PRODIGE 4/ACCORD 11 was the first phaseⅢtrial to provide unequivocal benefit using the polychemotherapy regimen FOLFIRINOX;however the less favorable safety profile and the characteristics of the enrolled population,restrict the use of FOLFIRINOX to young and fit PDAC patients.The nanoparticle albumin-bound paclitaxel(nab-Paclitaxel)formulation was developed to overcome resistance due to the desmoplastic stroma surrounding pancreatic cancer cells.Regardless of whether or not this is its main mechanisms of action,the combination of nabPaclitaxel plus Gem showed a statistically and clinically significant survival advantage over single agent Gem and significantly improved all the secondary endpoints.Furthermore,recent findings on maintenance therapy are opening up potential new avenues in the treatment of advanced PDAC,particularly in a new era in which highly effective first-line regimens allow patients to experience prolonged disease control.Here,we provide an overview of recent advances in the systemic treatment of advanced PDAC,mostly focusing on recent findings that have set new standards in metastatic disease.Potential avenues for further development in the metastatic setting and current efforts to integratenew effective chemotherapy regimens in earlier stages of disease(neoadjuvant,adjuvant,and multimodal approaches in both resectable and unresectable patients)are also briefly discussed. | Vanja Vaccaro Isabella Sperduti Sabrina Vari Emilio Bria Davide Melisi Carlo Garufi Carmen Nuzzo Aldo Scarpa Giampaolo Tortora Francesco Cognetti Michele Reni Michele Milella | 2015 | World Journal of Gastroenterology2015，21，16： | 2 |
| 3 | Gemcitabine-based combinations for inoperable pancreatic cancer:have we made real progress?A meta-analysis of 20 phase 3 trials显示文摘 | Bria E Milella M Gelibter A | 2007 | Cancer2007，110，3： | 1 |
| 4 | Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors:an important role for mutations in minor clones显示文摘 | Marchetti A Milella M Felicioni L | | 0，，： | 1 |
| 5 | FOLFIRINOX versus gem- citabine for metastatic pancreatic cancer 显示文摘 | Vaccaro V Sperduti I Milella M | 2011 | N Engl J Med2011，365，8： | 1 |
| 6 | Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia显示文摘 | Milella M Estrov Z Kornblau SM | 2002 | Blood2002，99，9： | 1 |
| 7 | First Line gefitinib (G) for advanced non small cell lung cancer (NSCLC) patients (pts) har- bouring sensitizing epidermal growth factor receptor mutations (EGFR M) Meta-analysis of randomized trials (RCT) explo- ring the magnitude of benefits over chemotherapy (CT) 显示文摘 | Ciannarelli D Bria E Milella M | 2010 | J Clin Oncol2010，，： | 1 |
| 8 | Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research 显示文摘 | Bonomi M Pilotto S Milella M | 2011 | J Exp Clin Cancer Res2011，30，1： | 1 |
| 9 | Evolutionary analysis of cytochrome b sequences in some perciformes: Evidence for a slower rate of evolution than in mammals显示文摘 | P. Cantatore M. Roberti G. Pesole A. Ludovico F. Milella M. N. Gadaletal C. Saccone | 1994 | Journal of Molecular Evolution1994，，6： | 1 |
| 10 | A study of the role of dif- ferent forms of chronic rhinitis in the development of otitis media with effusion in children affected by adenoid hypertrophy显示文摘 | Quaranta N Milella C Iannuzzi L | 2013 | Int J Pediatr Otorhinolaryngol2013，77，12： | 1 |
| 11 | FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer显示文摘 | Vaccaro V Sperduti I Milella M | 2011 | N Engl J Med2011，365，8： | 1 |
| 12 | Poly(L-lactide)acid/alginate composite membranes for guided tissue regeneration显示文摘 | Milella E Barra G Ramires PA | 2001 | J Biomed Mater Res2001，57，2： | 1 |
| 13 | Morphological and structural study of plasma deposited fluorocarbon films at different thicknesses显示文摘 | Cicala G Milella A Palumbo F | 2003 | Diamond and Related Materials2003，12，1011： | 1 |
| 14 | HPLC analysis of polypHenols in peel and pulp of fresh figs显示文摘 | Piga A Del Caro A Milella G et aI | 2008 | Acta Hort2008，，798： | 1 |
| 15 | Cytotkine-regulated expression of survivln in myeloid leukemia显示文摘 | Carter BZ Milella M Ahieri DC et a1 | 2001 | Blood2001，97，9： | 1 |
| 16 | Anti-Hbe-Positive Chronic hepatits B with HBVDNA in the serum response to a 6 month course of lymphoblastiold interforon 显示文摘 | Pastore G Santantonio T Milella M | 1992 | J Hepatol1992，14，： | 1 |
| 17 | Evolutionary analysis of cytochrome b sequences in some perciformes: Evidence for a slower rate of evolution than in mammals显示文摘 | P. Cantatore M. Roberti G. Pesole A. Ludovico F. Milella M. N. Gadaletal C. Saccone | 1994 | Journal of Molecular Evolution1994，，6： | 1 |
| 18 | Be-yond single path-way inhibition:MEK inhibitors as a platform for the development ofpharmacological combinations with synergistic anti-leukemiceffects显示文摘 | Milella M Precupanu CM Gregorj C | 2005 | Curr Pharm Des2005，11，： | 1 |
| 19 | Cytokine-regulated expression of survivin in myeloid leukemia显示文摘 | Carter BZ Milella M Altieri DC | | 0，，： | 1 |
| 20 | Trastuzumab cardio toxicity:biological hypotheses and clinical open issues显示文摘 | Bria E Cuppone F Milella M | 2015 | Expert Opin Biol Ther2015，8，12： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员